BiotechTube

TKI

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lung Cancer (NSCLC)

Conditions

Lung Cancer (NSCLC)

Trial Timeline

May 1, 2025 → Dec 1, 2028

NCT ID
NCT06969781

About TKI

TKI is a pre-clinical stage product being developed by Shanghai Allist Pharmaceuticals for Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06969781. Target conditions include Lung Cancer (NSCLC).

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06969781Pre-clinicalRecruiting

Competing Products

20 competing products in Lung Cancer (NSCLC)

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
PemetrexedEli LillyPre-clinical
23
pemetrexed + erlotinibEli LillyPhase 2
52
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
52
LY3295668 ErbumineEli LillyPhase 1
33
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
69
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
TNG456 + abemaciclibEli LillyPhase 1/2
41

Other Products from Shanghai Allist Pharmaceuticals

Furmonertinib + AnlotinibPhase 2
49